Revvity, Inc. RVTY recently introduced Signals Xynthetica, a next-generation AI-augmented design platform aimed at transforming molecular and materials discovery across scientific industries.

Acquisition deepens Revvity Signals’ presence in research informatics while furthering its ongoing expansion into development and manufacturing solutions ACD/Labs brings deep expertise in supporting ...

Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through ...

New AI Models-as-a-Service offering to integrate in-silico design with experimental data to continuously improve predictive power and accelerate scientific innovation Across life sciences and ...

A federated AI framework integrates predictive drug discovery models directly into a widely used research platform. The approach lets teams apply advanced AI while keeping proprietary data private.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives ...

Revvity Balances Earnings Strength With Cautious 2026 Outlook Revvity’s latest earnings call painted a picture of a company executing well financially while bracing for a tough macro and sector ...

Revvity, Inc. RVTY is well-positioned for growth in the coming quarters, thanks to its strong product portfolio. The optimism, led by its solid fourth-quarter 2024 performance and focus on artificial ...